Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) received an average rating of “Hold” from the nine ratings companies that cover the stock, Marketbeat Ratings reports. One equity research analyst rated the stock with a sell rating, three issued a hold rating and four issued a buy rating on the company. The 1-year average price target among brokerages that have hedged the stock over the past year is $10.13.
KPTI has been the subject of several research analyst reports. StockNews.com upgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a Monday, November 7 research report. Barclays cut its price target on Karyopharm Therapeutics from $14.00 to $8.00 and set an “overweight” rating for the company in a Friday, Aug. 5 research report. Morgan Stanley cut its price target on Karyopharm Therapeutics from $10.00 to $7.00 and set an “equal weight” rating for the company in a Friday, September 9 research report. Royal Bank of Canada upgraded Karyopharm Therapeutics from an ‘sector performer’ rating to an ‘outperformer’ rating and raised its price target for the company from $7.00 to $10.00 in a report Friday, November 4. Finally, HC Wainwright reduced its price target on Karyopharm Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a Friday, August 5 report.
Institutional investors weigh in on Karyopharm Therapeutics
Institutional investors have recently changed their stock portfolios. Nisa Investment Advisors LLC increased its stake in shares of Karyopharm Therapeutics by 612.5% in Q3. Nisa Investment Advisors LLC now owns 5,700 shares of the company valued at $26,000 after purchasing an additional 4,900 shares in the last quarter. Prelude Capital Management LLC purchased a new stake in shares of Karyopharm Therapeutics in Q2, valued at approximately $53,000. Mackenzie Financial Corp bought a new equity stake in Karyopharm Therapeutics in Q2 valued at around $54,000. Virtu Financial LLC purchased a new stake in shares of Karyopharm Therapeutics in Q2 valued at approximately $59,000. Finally, Running Point Capital Advisors LLC purchased a new equity stake in Karyopharm Therapeutics in Q1 worth approximately $74,000. 84.66% of the shares are held by institutional investors.
Karyopharm Therapeutics down 1.4%
NASDAQ: KPTI opened at $5.66 on Friday. Karyopharm Therapeutics has a 12 month minimum of $4.00 and a 12 month maximum of $14.73. The stock has a 50-day moving average price of $5.05 and a 200-day moving average price of $5.19. The stock has a market capitalization of $459.31 million, a P/E ratio of -4.96 and a beta of -0.13.
Karyopharm Therapeutics Company Profile
(Get an evaluation)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops and markets nuclear export-directed drugs for the treatment of cancer and other diseases. The Company discovers, develops and commercializes novel Selective Nuclear Export Inhibitor (SINE) compounds that work by binding to and inhibiting the nuclear export protein XPO1.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Karyopharm Therapeutics, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Karyopharm Therapeutics wasn’t on the list.
Although Karyopharm Therapeutics currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here